Stock listing

Milan:1BMRN BioMarin Pharmaceutical Inc. Azioni

Italian listing (Milan) of BioMarin Pharmaceutical Inc. · home listing NASDAQ:BMRN

Follow BioMarin Pharmaceutical Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:BMRN

$54.67 USD -0.01 (-0.0%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:BMRN

Since Jul 6, 2026 -7.0% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$54.08 – $55.12 USDOct 19, 2026
Volume
3.00M sharesOct 19, 2026
Market value
$10.58B USDAt the close on Oct 19, 2026 · price × 193.6M shares outstanding
BioMarin Pharmaceutical Inc. logo
Ticker
Milan:1BMRN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Milan
Currency
EUR

What changed lately

Calls

Replays

  • BioMarin Pharmaceutical (NASDAQ:BMRN) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 4:30 PM ET

    Watch Transcript

  • BioMarin Pharmaceutical (NASDAQ:BMRN) Q1 2026 Earnings Call

    Mon, May 04, 2026 · 4:30 PM ET

    Watch Transcript

  • BioMarin Pharmaceutical (NASDAQ:BMRN) Q4 2025 Earnings Call

    Mon, Feb 23, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

Oct 9, 2026

BioMarin Appoints Cara Bauer as Chief People Officer

Oct 5, 2026

BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress

Oct 2, 2026

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

Sep 14, 2026

BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence

Sep 9, 2026

BioMarin Announces Close of the Alesta Therapeutics Acquisition

Sep 1, 2026

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea

Aug 30, 2026

BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline

Aug 18, 2026

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8: 00AM ET in Boston

Aug 10, 2026

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Aug 6, 2026

All BioMarin Pharmaceutical Inc. news

Decks

BioMarin Pharmaceutical Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
40 in the last 12 months · 238 in all · newest Oct 9, 2026 · oldest 2019
Calls
23 calls with a replay · 23 with a transcript · latest Aug 6, 2026
Decks
50 decks · latest Aug 6, 2026

Where BioMarin Pharmaceutical Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BMRN · Home listingNASDAQUnited StatesUSD
gettex:BM8gettexGermanyEUR
Tradegate:BM8TradegateGermanyEUR
LS Exchange:924801LS ExchangeGermanyEUR
Frankfurt:BM8FrankfurtGermanyEUR
BMV:BMRNBMVMexicoMXN
Lang & Schwarz:924801Lang & SchwarzGermanyEUR
B3:B1MR34B3BrazilBRL
LSE:0HNCLSEUnited KingdomUSD
Milan:1BMRN · This pageMilanItalyEUR
BX Swiss:BM8BX SwissSwitzerlandCHF
EUROTLX:4BMRNEUROTLXItalyEUR
Munich:BM8MunichGermanyEUR
VIE:BMRNViennaAustriaEUR
BOATS:BMRNBOATSUnited StatesUSD
Dusseldorf:BM8DusseldorfGermanyEUR
Hamburg:BM8HamburgGermanyEUR
Hanover:BM8HanoverGermanyEUR
Stuttgart:BM8StuttgartGermanyEUR
BIVA:BMRNBIVAMexicoMXN

Log in to ask 6ix AI your own questions about BioMarin Pharmaceutical Inc.